We believe the key to treating neurodegenerative disease is to intervene early.
Millions of people worldwide suffer from neurodegenerative diseases that impair memory, focus and thinking. We believe that we can reverse the synaptic dysfunction responsible for early-stage disease symptoms and progression.Our Approach
A FOCUS ON
Hope Through Science
We’re developing neﬂamapimod—an oral, selective small molecule inhibitor of the protein kinase p38 alpha. Extensive research has shown that p38 alpha is a key driver of synaptic dysfunction. These data, along with evidence from a recent phase 2a clinical study, strongly suggest that inhibition of p38 alpha by neﬂamapimod can reverse the synaptic dysfunction that causes neurodegenerative disease progression in the early stages.Treatment & Results
EIP Pharma in the News
EIP Pharma Announces Presentation of Preclinical Data Demonstrating Effects of p38α Kinase Inhibitor Neflamapimod on the Neurodegenerative Process
July 17, 2019